Conatus Pharmaceuticals (CNAT) Tops Q1 EPS by 8c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q1 EPS of ($0.14), $0.08 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.15 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Presidents Capital Management Reiterates Strong Buy (1) Rating on Sea Ltd. (SE)
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform